Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Leukemia Research Année : 2016

Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Résumé

This retrospective study describes efficacy of Azacitidine on autoimmune disorders (AID) associated with MDS/CMML in 22 patients. Response of AID to Azacitidine was observed in 19 patients (86%). Reduction or discontinuation of steroids and/or immunosuppressive therapy (IST) was possible in 16 cases (73%). Hematologic response was seen in 55% of the patients. MDS/CMML and AID evolution was concordant in 13 cases (59%): both favorable (n = 11), both unfavorable (n = 2), but AID improved while MDS/CMML worsened (n = 8) and vice versa (n = 1). Azacitidine frequently seems effective in controlling steroid-dependent AID associated with MDS/CMML, but prospective studies are necessary to confirm those findings

Domaines

Cancer
Fichier principal
Vignette du fichier
Efficacy of Azacitidine in Autoimmune and Inflammatory.pdf (244.84 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-01278608 , version 1 (07-06-2016)

Identifiants

Citer

Jean-Baptiste Fraison, Arsène Mekinian, Eric Grignano, Jean-Emmanuel Kahn, Jean-Benoit Arlet, et al.. Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Leukemia Research, 2016, 43, pp.13-17. ⟨10.1016/j.leukres.2016.02.005⟩. ⟨hal-01278608⟩
721 Consultations
1381 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More